ctDNA
circulating tumor DNA — Fragments of tumor DNA in the blood, used for non-invasive cancer detection and monitoring.
Coverage of ctDNA is holding steady : 28 signals on the latest tracked day, up 100% from its three-week baseline of 14, across 3 domains (unchanged from a week ago). That makes it the #76 most-covered of the 274 concerns we track.
What’s changed
- ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC. · Thorac Cancer · 2026-08-01
- Discordant Dynamics Between Absolute ctDNA and Tumor Fraction During Treatment Monitoring in Metastatic Colorectal Cancer: Evidence of a Dilution Phenomenon · Clinical Colorectal Cancer · 2026-07-25
- ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word · Annals of Oncology · 2026-07-12
- ctDNA-derived copy-number signatures associated with immune checkpoint inhibitor resistance beyond PD-L1 and TMB in advanced NSCLC · Frontiers Precision Oncology · 2026-07-31 · usually covers Precision Medicine
- FIND Trial: ctDNA-Guided Surveillance After Curative-Intent Colorectal Cancer Surgery - Oncodaily · CRC Research (Google News) · 2026-07-31 · usually covers Gi Journal
- Minimally invasive monitoring of clonal evolution through integrated single cell and ctDNA analysis · bioRxiv — Cancer Biology · 2026-07-30 · usually covers Preprint
What the reporting says
It shows up alongside Colorectal Cancer (100), Immunotherapy (16), KRAS (14), Egfr (9), AI (14).
Two steps out: MSI-H (through Colorectal Cancer, 54 shared stories on the weaker link); FDA (through Colorectal Cancer, 37 shared stories on the weaker link); China (through Colorectal Cancer, 33 shared stories on the weaker link); Nuclear (through Colorectal Cancer, 21 shared stories on the weaker link).
Tracked since Mar 11, with coverage on 86 separate days — concentrated in Oncology and Pubmed Targeted.